ATE470665T1 - Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 - Google Patents

Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53

Info

Publication number
ATE470665T1
ATE470665T1 AT07727060T AT07727060T ATE470665T1 AT E470665 T1 ATE470665 T1 AT E470665T1 AT 07727060 T AT07727060 T AT 07727060T AT 07727060 T AT07727060 T AT 07727060T AT E470665 T1 ATE470665 T1 AT E470665T1
Authority
AT
Austria
Prior art keywords
mdm2
interaction
cycloalkylamin
inhibitors
derivatives
Prior art date
Application number
AT07727060T
Other languages
German (de)
English (en)
Inventor
Jean Lacrampe
Christophe Meyer
Bruno Schoentjes
Alain Poncelet
Camille Wermuth
Bruno Giethlen
Jean-Marie Contreras
Muriel Joubert
Hijfte Luc Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE470665T1 publication Critical patent/ATE470665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07727060T 2006-03-22 2007-03-19 Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 ATE470665T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111529 2006-03-22
US78512006P 2006-03-23 2006-03-23
PCT/EP2007/052582 WO2007107545A1 (en) 2006-03-22 2007-03-19 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53

Publications (1)

Publication Number Publication Date
ATE470665T1 true ATE470665T1 (de) 2010-06-15

Family

ID=38110050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07727060T ATE470665T1 (de) 2006-03-22 2007-03-19 Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53

Country Status (8)

Country Link
US (2) US8088795B2 (https=)
EP (1) EP1999126B1 (https=)
JP (1) JP5162574B2 (https=)
AT (1) ATE470665T1 (https=)
AU (1) AU2007228784B2 (https=)
CA (1) CA2644649C (https=)
DE (1) DE602007007065D1 (https=)
WO (1) WO2007107545A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
JP5438008B2 (ja) * 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
TWI476189B (zh) 2009-02-04 2015-03-11 Janssen Pharmaceutica Nv 用作抗癌劑之吲哚衍生物
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
CA2805658C (en) * 2010-07-21 2016-12-13 Joseph P. Errico Combination therapy with mdm2 and egfr inhibitors
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US10016414B2 (en) * 2010-11-12 2018-07-10 University Of Massachusetts Modulation of ubiquitination of synaptic proteins for the treatment of neurodegenerative and psychiatric disorders
CN103221094B (zh) * 2010-11-19 2016-04-20 诺华有限公司 Mdm2/4及p53相互作用抑制剂的结晶型
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
JP6564029B2 (ja) 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016181414A1 (en) * 2015-05-12 2016-11-17 Council Of Scientific & Industrial Research Process for the synthesis of ivacaftor and related compounds
DK3331876T3 (da) 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma
TW202332444A (zh) * 2015-10-23 2023-08-16 日商第一三共股份有限公司 用於治療癌症之醫藥組成物
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115650976A (zh) 2017-07-24 2023-01-31 生命医药有限责任公司 RORγ的抑制剂
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CN1329493A (zh) 1998-12-02 2002-01-02 辉瑞产品公司 恢复p53家族蛋白质的构象稳定性的方法和组合物
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
WO2003040402A2 (en) * 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
NZ532463A (en) 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
PL370823A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
GB0419481D0 (en) * 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53

Also Published As

Publication number Publication date
US8377961B2 (en) 2013-02-19
CA2644649C (en) 2014-06-17
US8088795B2 (en) 2012-01-03
US20120071508A1 (en) 2012-03-22
WO2007107545A1 (en) 2007-09-27
EP1999126B1 (en) 2010-06-09
AU2007228784A1 (en) 2007-09-27
JP2009530345A (ja) 2009-08-27
DE602007007065D1 (de) 2010-07-22
CA2644649A1 (en) 2007-09-27
EP1999126A1 (en) 2008-12-10
JP5162574B2 (ja) 2013-03-13
US20100168163A1 (en) 2010-07-01
AU2007228784B2 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
SG155941A1 (en) Inhibitors of the interaction between mdm2 and p53
ATE542799T1 (de) Chinolinonderivate als parp und tank-inhibitoren
JO2704B1 (en) Interference inhibition factors between MD2 and B53
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
SG154434A1 (en) Quinazolinone derivatives as parp inhibitors
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
EA201070278A1 (ru) Ингибиторы гамма-секретазы
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200970156A1 (ru) Пиридизиноновые производные
ATE547395T1 (de) Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
ATE533759T1 (de) Imidazolinon- und hydantoinderivate als neue inhibitoren von histondeacetylase
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer
NO20082185L (no) Heterocykliske CETP-inhibitorer
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties